Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 15 systematic review(s)/meta-analysis(es). ^[1-15]
• Youth with Bipolar Disorder Type I: Aripiprazole demonstrated significant effectiveness in reducing manic symptoms (SMD (standardized mean difference) = -0.67, 95% CI = -0.33, -1.01) and increased mania response rates (RR (relative risk) = 2.05, 95% CI (confidence interval) = 1.44, 2.92). Risperidone showed the highest efficacy in manic symptom reduction (SMD = -1.18) and mania response (RR = 2.58), with other SGAs (second-generation antipsychotics) showing similar trends.
• Schizophrenia Spectrum Disorders (General Population): Aripiprazole was effective in dual LAI AP (Long-acting injectables antipsychotics) treatments, particularly in combination with paliperidone palmitate, for treatment-resistant schizophrenia, with no new or unexpected adverse events reported.
• Acute Schizophrenia Symptoms: Aripiprazole LAI reduced symptoms more effectively than placebo (SMD = -0.64, 95% CI = -0.80, -0.48). Other LAIs such as olanzapine, risperidone, and paliperidone also demonstrated significant symptom reduction, with comparable effectiveness across these treatments.
• Rapid Cycling Bipolar Disorder: Aripiprazole showed notable benefits in reducing mania symptoms (g = 1.09), while quetiapine and olanzapine also presented significant reductions in mania symptoms in this population.
• Youth with Bipolar Disorder Type I: Aripiprazole was associated with increased risks of sedation, weight gain, and metabolic issues compared to placebo and mood stabilizers, with similar safety concerns observed across other SGAs.
• Adults with Schizophrenia or Schizoaffective Disorder: Aripiprazole demonstrated a lower risk of treatment discontinuation due to adverse events compared to other LAIs, though it had a higher risk of treatment-emergent adverse events than most other LAIs.
• There is no population type or subgroup information available in the reviewed studies.